CClinicalTrials.gg
Enrolling by invitationNCT07802522Updated Sep 3, 2026

Hyperangulated Video Laryngoscopes Used for Intubation With Simultaneous Cervical Spine Immobilization

An interventional study of Airway management in Cervical Spine Immobilisation, Airway Management and Difficult Airway, sponsored by Uniwersytet Radomski im. Kazimierza Pułaskiego. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Uniwersytet Radomski im. Kazimierza Pułaskiego · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. Patients with known difficult laryngoscopy, difficult face mask ventilation, with previous history of awake tracheal intubation, those aged under 18 years or patients with BMI > 30 kg m-2 will be excluded from the study. All patients will receive oral premedication with 7.5 mg midazolam 30 minutes before the start of anaesthesia. A standard monitoring will be applied. This consists of ECG, NIBP (non-invasive blood pressure), SpO2, TOF (train-of-four) and volatile anaesthetic concentration. In order to achieve cervical spine immobilization, a Patriot® cervical collar (Össur hf., Reykjavik, Iceland) will be applied. The size of the collar will be adjusted to the patient's anatomy. Furthermore, the cervical collar will be fixed to allow a minimal mouth opening of 20 mm. All patients will be placed in a neutral position and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. Anaesthesia will be induced with fentanyl (1-2 µg ml-1) and propofol (2-3 mg ml-1). Rocuronium (0.6 mg ml-1) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 7.5 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained beforehand with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasts more than 60 seconds, when saturation drops below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurrs. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.

Read the detailed description

This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. Patients with known difficult laryngoscopy, difficult face mask ventilation, with previous history of awake tracheal intubation, those aged under 18 years or patients with BMI > 30 kg m-2 will be excluded from the study. All patients will receive oral premedication with 7.5 mg midazolam 30 minutes before the start of anaesthesia. A standard monitoring will be applied. This consists of ECG, NIBP (non-invasive blood pressure), SpO2, TOF (train-of-four) and volatile anaesthetic concentration. In order to achieve cervical spine immobilization, a Patriot® cervical collar (Össur hf., Reykjavik, Iceland) will be applied. The size of the collar will be adjusted to the patient's anatomy. Furthermore, the cervical collar will be fixed to allow a minimal mouth opening of 20 mm. All patients will be placed in a neutral position and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. Anaesthesia will be induced with fentanyl (1-2 µg ml-1) and propofol (2-3 mg ml-1). Rocuronium (0.6 mg ml-1) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 7.5 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained beforehand with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasts more than 60 seconds, when saturation drops below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurrs. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.

The primary outcomes are the intubation time (Ti) and the first-attempt success. The Ti is defined as the time from picking up the videolaryngoscope until the correct placement of the tracheal tube will be confirmed by capnography. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure Ti. The secondary outcomes include the ease-of-use and the time required to achieve the glottic view (Tg). The former will be evaluated using the NRS (Numerical Rating Scale). This is an eleven-point scale, i.e. from 0 to 10, and the score 0 denotes a very difficult and complicated to use device while 10 corresponds to an user-friendly equipment. The Tg is defined as the time from picking up the videolaryngoscope until the optimal entry-to-the-larynx view is achieved.

Collected data will be analysed using Statistica 14.0 (TIBCO Software, Palo Alto, CA, USA) and Microsoft Office Excel 2021 spreadsheet (Microsoft, Redmond, WA, USA). The Wilcoxon signed-rank test and the paired Student t-test will be used for data analysis. Continuous variables will be presented either as mean ± SD (standard deviation) or median (IQR - interquartile range) for non-normally distributed data. The Kolmogorov-Smirnov test will determine whether the analysed variables matches the characteristics of a normal distribution. We assume that the overall success rate of intubation in obese patients will be 90% (α = 0.05, 2-sided, β = 0.1, 95% CI). The calculated sample size requires 195 participants and the final adjusted sample size will be 200 patients to compensate for dropouts. A p-value of less than 0.05 (p \< 0.05) is considered statistically significant.

02

Conditions studied

  • Cervical Spine Immobilisation
  • Airway Management
  • Difficult Airway

Keywords

  • videolaryngoscope
  • difficult airway
  • hyperangulated blade
  • cervical spine immobilisation
  • intubation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ASA status 1-3
  • aged over 18 years old
  • male and female
  • laparoscopic surgery

Exclusion criteria

Exclusion Criteria:

  • known difficult laryngoscopy
  • difficult face mask ventilation
  • aged under 18 years old
  • previous history of awake tracheal intubation
  • patients with BMI > 30 kg m-2
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    VisionPro

    Device used for intubation

    Device: Airway management

  • Active comparator
    C-MAC

    Device used for intubation

    Device: Airway management

  • Active comparator
    McGrath

    Device used for intubation

    Device: Airway management

  • Active comparator
    AceScope

    Device used for intubation

    Device: Airway management

Interventions

  • DeviceAirway management

    Device used for intubation

05

What researchers measure

Primary outcomes

  1. First-attempt success

    This is the percentage of successful tracheal tube placement at the first attempt.

    Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months

  2. Intubation time

    The intubation time is defined as the time from picking up the videolaryngoscope until the correct placement of the tracheal tube has been confirmed by capnography. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure the intubation time.

    Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months

Secondary outcomes

  1. User-friendliness of the device used

    It will be evaluated using the Numerical Rating Scale (NRS). This is an eleven-point scale, i.e. from 0 to 10, and regarding the ease-of-use 0 denotes a very difficult and complicated to use device while 10 corresponds to an user-friendly equipment.

    Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months

  2. The time required to achieve the glottic view

    This is defined as the time from picking up the videolaryngoscope until the optimal entry-to-the-larynx view has been achieved. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure this parameter.

    Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months

06

Study locations

1 site
  • Uniwersytet Radomski
    Radom, Masovian Voivodeship 26-600, Poland
07

Registry details

Key details

Study ID
NCT07802522
Lead sponsor
Uniwersytet Radomski im. Kazimierza Pułaskiego
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Aug 31, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Sep 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion